Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$15.93 - $22.26 $52,569 - $73,458
-3,300 Reduced 32.67%
6,800 $150,000
Q1 2024

May 15, 2024

SELL
$15.55 - $19.42 $18,660 - $23,304
-1,200 Reduced 10.62%
10,100 $184,000
Q4 2023

Feb 14, 2024

BUY
$17.18 - $22.38 $8,590 - $11,190
500 Added 4.63%
11,300 $223,000
Q3 2023

Nov 14, 2023

BUY
$15.0 - $20.71 $16,500 - $22,781
1,100 Added 11.34%
10,800 $212,000
Q2 2023

Aug 14, 2023

SELL
$10.84 - $15.43 $118,156 - $168,187
-10,900 Reduced 52.91%
9,700 $147,000
Q1 2023

May 15, 2023

SELL
$9.32 - $12.58 $148,188 - $200,022
-15,900 Reduced 43.56%
20,600 $235,000
Q4 2022

Feb 14, 2023

BUY
$6.82 - $12.07 $26,598 - $47,073
3,900 Added 11.96%
36,500 $336,000
Q3 2022

Nov 14, 2022

BUY
$6.9 - $18.16 $57,960 - $152,544
8,400 Added 34.71%
32,600 $225,000

Others Institutions Holding PETQ

About PetIQ, Inc.


  • Ticker PETQ
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 29,312,800
  • Market Cap $908M
  • Description
  • PetIQ, Inc. operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which include flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medicat...
More about PETQ
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.